CytRx (CYTR) Initiates Dxorubicin Conjugate INNO-206 Phase 2b

CytRx Corporation (Nasdaq: CYTR) has announced the initiation of an international Phase 2b clinical trial to evaluate the preliminary efficacy and safety of its tumor-targeting doxorubicin conjugate INNO-206 in patients with late-stage soft tissue sarcoma. The Phase 2b clinical trial will provide the first direct clinical trial comparison of INNO-206 with native doxorubicin, which is dose-limited due to toxicity, as a first-line therapy.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
• Repros Therapeutics (RPRX) Modifies Pivotal Androxal Protocol
• IsoRay (ISR) Says GliaSite System Received CE Mark; to Go On Sale in 31 European Markets

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter